IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy.

@article{Okita2012IDH12MI,
  title={IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy.},
  author={Yoshiko Okita and Yoshitaka Narita and Yasuji Miyakita and Makoto Ohno and Yuko Matsushita and Shintaro Fukushima and Minako Sumi and Koichi Ichimura and Takamasa Kayama and Soichiro Shibui},
  journal={International journal of oncology},
  year={2012},
  volume={41 4},
  pages={
          1325-36
        }
}
Reliable prognostic biomarkers of grade II gliomas remain unclear. This study aimed to examine the role of mutations of isocitrate dehydrogenase (IDH1/2), 1p/19q co-deletion, and clinicopathological factors in patients with grade II glioma who were primarily treated with radiotherapy or chemoradiotherapy after surgery. Seventy-two consecutive patients, including 49 cases of diffuse astrocytomas (DA), 4 oligodendrogliomas (OL) and 19 oligoastrocytomas (OA), who underwent treatment from 1991 to… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 30 CITATIONS